Compare Ginkgo Bioworks Holdings Inc (DNA) vs Nomura Holdings Inc (NMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Nomura Holdings Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $13 (market cap $763.64M), while Nomura Holdings Inc trades at $9.59 (market cap $27.55B). The key difference: Nomura Holdings Inc is far larger — about 36.1× Ginkgo Bioworks Holdings Inc's market cap, and Nomura Holdings Inc pays a 3.4% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and Nomura Holdings Inc for 55 Days on average.
| DNA | NMR | |
|---|---|---|
Market Cap | $763.64M | $27.55B |
Volume | 3,204,177 | 782,470 |
Sector | Health | Financials |
52-Week High | $15.83 | $10.86 |
52-Week Low | $5.48 | $6.73 |
Typical Hold Time | 7 Days | 55 Days |
Enterprise Value | $865.59M | $38.54T |
Dividend Yield | — | 3.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $11.34, down 1.13% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $312.76 million on $170.16 million revenue for 2025, with negative cash flow. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting ongoing strategic initiatives despite financial challenges.
The outlook remains speculative given persistent losses and cash burn, though analyst consensus is divided. Key risks include execution on revenue growth and path to profitability. Upside depends on successful commercialization of its biotech platform and partnerships, but high volatility and fundamental weakness warrant caution for investors.
Nomura Holdings (NMR) trades at $9.54, up 0.1% on the day, with a bearish technical signal but strong fundamental metrics including a P/E of 11.33 and net income margin of 20.4%. Recent earnings show a mix of beats and misses, while cash flow trends indicate significant financing activity. The stock is near its support level of $9, with RSI indicators suggesting potential oversold conditions. Zacks Research highlighted NMR as a strong buy for momentum and value in September 2026, citing recent price strength.
The outlook for NMR is cautiously optimistic, supported by solid profitability and valuation, but tempered by bearish technicals and inconsistent earnings performance. Key risks include high debt levels and macroeconomic sensitivity, while analyst sentiment leans hold. Upside potential exists if earnings stabilize and technical support holds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →
